Cassels partner Andrew Skodyn was featured in Canadian Lawyer in an article discussing the Supreme Court of Canada’s recent 7-2 decision in Pharmascience Inc. v. Janssen Inc., which confirms that methods of medical treatment remain unpatentable in Canada while upholding the patentability of Janssen’s dosing regimen for a schizophrenia treatment.
The decision provides important guidance for life sciences and intellectual property stakeholders, clarifying when pharmaceutical dosing regimens may fall outside the prohibition on patenting methods of medical treatment.
In the article, Andrew notes that the decision represents a “missed opportunity” to simplify Canada’s patent regime.
Read the full article here: “SCC Affirms 7-2 That Methods of Medical Treatment Cannot be Patented in Canada.”
_
Read our full Comment on this decision here: “The More Things Change, The More They Stay the Same: The Supreme Court Determines the Patentability of Methods of Medical Treatment.”
Cassels lawyers Andrew Skodyn, Sean Jackson, and Eleanor Wilson represented the International Federation of Intellectual Property Attorneys (FICPI), an intervener in this appeal.